ICON plc is a contract research organization (CRO) founded in 1990 that provides outsourced development, consulting, and commercialization services to pharmaceutical, biotechnology, medical device, and government public health organizations. The company offers clinical development services across Phases I-IV, peri- and post-approval activities, data solutions, and site and patient access services. Its laboratory services include bio-analytical, biomarker, vaccine, GMP, and central laboratory testing. ICON also provides functional outsourcing and full-service partnerships, including decentralized clinical trials, manufacturing and pharmacy services, and asset development consulting. The company serves customers globally, with a focus on therapeutic areas such as oncology, endocrine and metabolic disorders, internal medicine, immunology, and neurodegenerative diseases. Recent acquisitions include KCR S.A Group, HumanFirst, Inc., BioTel Research, LLC (formerly Philips Pharma Solutions), and Oncacare Limited. ICON has established relationships with major pharmaceutical and biotech companies worldwide.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Diagnostics & Research Homepage iconplc.com
Sector Healthcare IR page investor.iconplc.com
Tags
clinical research, contract research organization, clinical trial management, biomarker testing, vaccine development, gmp testing, decentralized clinical trials, patient recruitment, pharmacovigilance, medical imaging, cardiac safety monitoring, oncology research, KCR S.A Group, HumanFirst, BioTel Research, Philips Pharma Solutions, Oncacare, PRA Health Sciences, ICON Cares
Press page iconplc.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 15.512B
Market cap (USD) $ 15.512B
P/E 81.52
PEG —
P/BV 1.70
P/S 1.88
P/OCF 14.97
P/FCF 18.00
Dividend yield —
Turnover / mcap —
Returns  
ROE 2.5%
ROI 1.8%
ROIC 3.2%
Profit margin 2.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -23.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 37.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 8.251B 8.282B 8.12B 7.741B 5.481B 2.797B 2.806B 2.596B 1.758B 1.666B 1.575B 1.503B 1.336B 1.115B 945.729M 900.044M
Net profit 229.339M 791.474M 612.335M 505.304M 153.185M 332.331M 373.986M 322.656M 281.488M 262.179M 239.539M 172.468M 102.812M 55.42M 22.88M 87.071M
Free cash flow 861.991M 1.119B 1.02B 421.155M 735.392M 516.98M 361.896M 220.242M 338.365M 216.603M 229.801M 137.169M 191.739M 82.64M -15.093M 56.476M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 182.22 209.71 283.07 194.25 309.7 194.98 172.23 129.21 112.15 75.2 77.7 50.99 40.41 — — —
Price performance 12m -0.13 -0.26 0.46 -0.37 0.59 0.13 0.33 0.15 0.49 -0.03 0.52 0.26 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 416M 380M 415M 528M 715M 1.34B 1.73B 1.79B 1.4B 1.47B
↳ YoY growth +1.7% -8.8% +9.3% +27.2% +35.5% +87.7% +28.9% +3.4% -21.7% +5.2%
↳ 5y CAGR +15.6% +5.9% +3.9% +7.3% +11.8% +26.4% +35.5% +34.0% +21.6% +15.6%
Borrowings, non-current (USD) — — — — 348M 5.38B 4.6B 3.67B 3.4B 2.87B
Lease liabilities (USD) — — — 105M 85.1M 209M 175M 163M 177M 153M
Cash and deposits (USD) 193M 283M 396M 520M 840M 752M 289M 378M 539M 647M
Intangible assets (USD) 56.6M 71.6M 54.1M 67.9M 66.5M 4.71B 4.28B 3.86B 3.56B 3.25B
Right-of-use assets (USD) — — — 105M 84.6M 198M 154M 140M 148M 129M
Net debt (borrowings + leases - cash) (USD) — — — — -407M 4.84B 4.49B 3.45B 3.03B 2.38B
Cash flow detail
Operating cash flow (USD) 259M 383M 269M 413M 568M 829M 563M 1.16B 1.29B 1.04B
Purchases of property, plant and equipment (USD) -42.6M -44.7M -48.4M -50.6M -51.1M -93.8M -142M -141M -168M -174M
Change in receivables (cash effect) (USD) 2.53M 57.7M -37.6M -102M -175M 114M -421M -83.3M 349M -108M
Change in payables (cash effect) (USD) 1.18M 7.01M -5.07M 3.44M 26.5M — — — — —
Share buybacks (cash effect) (USD) -110M -133M -129M -147M -175M 0.00 -100M 0.00 -500M -750M
Interest paid (cash effect) (USD) -13.6M -13.1M -13.1M -13.1M -13.1M -106M -211M -318M -197M -193M
Income taxes paid (cash effect) (USD) -10.2M -12.3M -18.6M -29.8M -27.6M -55.1M -116M -164M -141M -166M
Share-based compensation (USD) 40.3M 30.6M 31.6M 26.8M 26.3M 134M 70.5M 55.7M 45.9M 102M
Operating cash flow before change in receivables (USD) 257M 325M 306M 514M 743M 716M 984M 1.24B 937M 1.14B
Free cash flow (OCF - PPE - intangibles) (USD) 217M 338M 220M 362M 517M 735M 421M 1.02B 1.12B 862M
Income detail
Total comprehensive income (USD) 238M 329M 292M 369M 373M 97.7M 425M 640M 705M 391M
Comprehensive income to owners (USD) 238M 329M 292M 367M 373M 97.7M 425M 640M 705M 391M
Provision for credit losses (USD) — 2.73M 995,000 — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) — 0.7% 0.3% — — — — — — —
Reported Feb 28, 2017 Mar 1, 2019 Mar 1, 2019 Feb 27, 2020 Mar 1, 2022 Mar 1, 2022 Feb 24, 2023 Feb 23, 2024 Feb 21, 2025 May 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

ICON to Participate at Upcoming Investor Conferences Bull 0 Bear 0 Routine

Dublin, Ireland, November 10, 2026 – ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that Mr. Barry Balfe, CEO of ICON plc, and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 at 12:30pm GMT and Mr. Barry Balfe, CEO of ICON plc, will participate at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026 at 1:20pm ET.

Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “Events”. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

About ICON plc

ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide.

###### Page tools

Share Share

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Facebook

Share on X

Facebook

Share on Facebook

Print

Search

Email

Accessibility

  • Date 5 November 2026
    Time 11:00 - 12:00
    Location Webinar
    Timezone EDT - America/New York

Overview

A well-designed Clinical Outcome Assessment (COA) strategy is critical to supporting regulatory decision-making. Yet COA strategies are often developed too late in the planning process, creating challenges that can compromise endpoint relevance, delay trial timelines, and limit the value of the evidence generated. 

This webinar will identify common pitfalls in developing COA strategies and will address practical questions sponsors face, such as:  

  • What decisions need to be made before an endpoint is locked?  
  • What evidence is needed to support instrument selection?  
  • When is it better to use an existing COA versus develop a new one?  
  • How early should localisation and linguistic validation be built into global study planning?

Learning objectives:

  • Identify the COA decisions that should be made early, and the consequences of making them too late  
  • Select or develop COA instruments that align with programme objectives 
  • Address regulatory evidence expectations 
  • Anticipate localisation and linguistic validation requirements for global studies 
  • Mitigate operational and regulatory risks through proactive planning 

Register today

Featuring insights from:

John Kealy, PhD

Principal, Patient Centred Endpoint Intelligence, Mapi Research Trust

John Kealy is a behavioural neuroscientist with expertise in neuropsychiatric and neurodevelopmental disorders. He has extensive clinical and preclinical experience in the drug discovery space, pioneering new methodologies including biosensors, neurochemical detection, and the development of translational biomarkers. At Mapi Research Trust, John leads the Patient-Centered Endpoint Intelligence (PACE) team providing consulting services around Clinical Outcome Assessments and Digital Health Technologies in clinical trials. 

Anne Sophie Michel, PharmD

Senior Outcomes Researcher, ICON Patient Centred Outcomes

Anne-Sophie Michel is a pharmacist by training and a Senior Outcomes Researcher at ICON with expertise in Patient-Focused Drug Development (PFDD). Her work focuses on incorporating the patient perspective into clinical research through robust qualitative methodologies and fit-for-purpose outcome assessment strategies. She advises sponsors on Clinical Outcome Assessment (COA) strategies and leads qualitative research projects, including interviews conducted alongside clinical trials, across a wide range of therapeutic areas to support drug development and regulatory decision-making.

Cristina Vasile

Account Manager, ICON Language Services

Cristina Vasile is an Account Manager at ICON Language Services with over 10 years of experience in linguistic validation for clinical outcomes assessments. She specialises in supporting complex global trials, helping sponsors align translation and validation strategies with early endpoint decisions to mitigate regulatory risk and deliver against critical study timelines.

In this section

In this section

Connect with us

Site Branding

ICON plc* Contact

For Clients

ICON for

News & Events

Socials

Legal Footer

Copy link

✓

Thanks for sharing!

Find any service

AddToAny

More…

Company Logo

ICON Cookies

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation and user experience, analyze site usage, and assist in our marketing efforts.

Accept All Cookies

Cookies Settings

Company Logo

ICON Privacy Preference Centre

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because ICON respects your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. Note, however, that blocking some types of cookies may impact your experience of the site and the services we are able to offer.
Cookie Notice

User ID: 20206441-5a9f-4fff-9eb3-5e2dad09af8f

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.    You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details‎

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.    All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details‎

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages.    If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details‎

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites.    They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details‎

Back Button

Cookie List

Filter Button

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Confirm My Choices

Reject All Allow All

Powered by Onetrust

ISPOR EU


8 November 2026. Register now.](https://www.iconplc.com/news-events/events/industry/ispor-eu-2026)

[![thumbnail](https://icon.widen.net/content/31d5a506-37c1-4014-b3fe-328596fe7009/web/Webinar_COAs_Images_thumbnail.jpg?crop=yes&w=260&h=136&itok=TH7gqJI2 "thumbnail")\
\
Getting COA strategy right from the start\
\
5 November 2026. Register now.](https://www.iconplc.com/news-events/events/webinars/getting-coa-strategy-right-start)
  1. Home

  2. News & Events

  3. Events

  4. ISPOR EU

ISPOR Europe

8 – 11 November 2026, Booth #1615, Austria Center Vienna, Vienna, Austria

###### Page tools

Share Share

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Facebook

Share on X

Facebook

Share on Facebook

Print

Search

Email

Accessibility

Advancing evidence. Elevating patient-centred value. Driving real-world impact.

ISPOR Europe brings together global leaders in health economics and outcomes research (HEOR) to shape how evidence informs policy, access, and healthcare decision-making. With thousands of stakeholders across research, HTA, industry, and patient communities, the conference explores how real-world evidence, patient-centred outcomes, and innovative methodologies are transforming value demonstration worldwide.

ICON is proud to participate in ISPOR Europe 2026, partnering with sponsors to generate the evidence needed to demonstrate value, accelerate access, and improve patient outcomes across the product lifecycle.

Register now

Connecting evidence to decisions in a changing healthcare landscape

As HEOR continues to evolve, organizations must go beyond evidence generation to deliver integrated evidence strategies that inform market access, pricing, and policy decisions. At ISPOR Europe 2026, key themes include:

  • The growing role of real-world evidence (RWE) across development and post-launch decision-making
  • Increased emphasis on patient-centred value and outcomes
  • The integration of AI and advanced analytics into evidence generation
  • Rising expectations for credible, timely, and decision-ready evidence
  • The intersection of policy, affordability, and access shaping global healthcare

These trends reflect a broader shift: evidence must not only be rigorous—but actionable, patient-relevant, and aligned with stakeholder needs. 

ICON supports this shift by combining scientific expertise, innovative methodologies, and deep therapeutic knowledge to help clients navigate increasingly complex evidence requirements.

ICON expertise across the HEOR ecosystem

Health Economics & Outcomes Research (HEOR)

ICON delivers integrated HEOR strategies that connect clinical, economic, and patient evidence to demonstrate value. From early evidence planning to HTA submissions, we help ensure that evidence is aligned with payer and policymaker expectations.

SVG Image

  ![Statistical analysis methodology update](https://icon.widen.net/content/tf4iwzaz5n/web/ICON_CRS_WebImages_Biostatistics.jpg?crop=yes&w=178&h=178&itok=pGpzDQN9 "Statistical analysis methodology update")

Patient-Reported Outcomes (PROs)

& Clinical Outcome Assessments (COAs)

Capturing the patient voice is central to modern value assessment. ICON designs and implements fit-for-purpose PRO and COA strategies, supporting both clinical trials and real-world studies to ensure outcomes reflect patients lived experience and treatment impact.

Emerging ISPOR guidance highlights the importance of robust real-world PRO methodologies to enhance credibility and decision relevance. It is an area where ICON provides deep scientific and operational leadership.

SVG Image

  ![Doctor using tablet with patient](https://icon.widen.net/content/hyc7jmd6zn/web/doctor-patient-ipad.jpg?crop=yes&w=178&h=178&itok=a8xpdsPi "Doctor using tablet with patient")

Real World Evidence (RWE)

With the explosion of real world data, organizations face increasing pressure to convert data into decision-grade evidence. ICON’s RWE capabilities span study design, data integration, analytics, and regulatory-grade evidence generation, helping clients demonstrate effectiveness, safety, and value in real-world settings.

ISPOR continues to emphasize that real-world data, when rigorously analysed, plays a critical role in informing healthcare decisions, complementing traditional clinical trial evidence. 

SVG Image

  ![real-world-intelligence](https://icon.widen.net/content/tl5wdmifpt/web/real-world-intelligence.jpg?crop=yes&w=178&h=178&itok=HvanpW0Z "real-world-intelligence")

Partner with ICON

From early development through post-launch, ICON delivers end-to-end evidence solutions that help you:

  • Generate credible, decision-focused evidence
  • Demonstrate value to payers and regulators
  • Incorporate patient experience into outcomes
  • Navigate evolving global market access requirements

Meet ICON at ISPOR Europe in Booth #1615

Connect with ICON’s HEOR, RWE, and Patient Centred Outcomes experts to explore how we can support your evidence strategy.

Discuss with our team:

  • Integrated HEOR and market access strategy
  • Real-world evidence generation and analytics
  • PRO/COA development and implementation
  • Evidence planning across the product lifecycle
  • Innovative approaches to value demonstration

Join us at ISPOR Europe 2026 to learn how ICON can help you translate evidence into impact.

Register now

Related information:

[Webpage
\

Outcome Measures](https://www.iconplc.com/solutions/outcome-measures)

[Webpage
\

Patient Centricity](https://www.iconplc.com/insights/patient-centricity)

[Case studies
\

Site & Patient Solutions](https://www.iconplc.com/solutions/all-case-studies/site-patient-solutions-case-studies)

[Whitepaper
\

Meeting requirements for Joint Clinical Assessments](https://www.iconplc.com/insights/regulatory-intelligence/meeting-requirements-joint-clinical-assessments)

Site Branding

ICON plc* Contact

For Clients

ICON for

News & Events

Socials

Legal Footer

Copy link

✓

Thanks for sharing!

Find any service

AddToAny

More…

Company Logo

ICON Cookies

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation and user experience, analyze site usage, and assist in our marketing efforts.

Accept All Cookies

Cookies Settings

Company Logo

ICON Privacy Preference Centre

  • Your Privacy

  • Strictly Necessary Cookies

  • Performance Cookies

  • Functional Cookies

  • Targeting Cookies

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because ICON respects your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. Note, however, that blocking some types of cookies may impact your experience of the site and the services we are able to offer.
Cookie Notice

User ID: 479686dc-5dd3-4d82-9e8e-9658d46f5315

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.    You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details‎

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.    All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details‎

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages.    If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details‎

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites.    They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details‎

Back Button

Cookie List

Filter Button

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Clear

checkbox label label

Apply Cancel

Confirm My Choices

Reject All Allow All

Powered by Onetrust

Prompts

ICON plc (ticker ICLR), listed in United States.

ETFs Holding ICON plc

ETF Weight in ETF Shares Market value As of
TLCI 4.28% 27,317 $ 4.745M Jun 30, 2026
CDIG 3.91% 10,496 $ 2.05M Nov 18, 2026
BASV 3.03% 71,181 $ 12.365M Jun 30, 2026
BUSA 2.11% 36,253 $ 6.298M Jun 30, 2026
EPIN 2.10% 877 $ 170.708K Nov 13, 2026
ORR 1.48% 27,611 $ 5.38M Nov 18, 2026
TMFG 1.28% 27,498 $ 4.537M Aug 31, 2026
DSTL 1.02% 124,845 $ 21.687M Jun 30, 2026
TIME 0.97% 750 $ 143.55K Nov 17, 2026
FPAG 0.94% 29,214 $ 5.075M Jun 30, 2026
MMSC 0.71% 1,849 $ 353.899K Nov 16, 2026
ABCS 0.68% 513 $ 84.64K Aug 31, 2026
HWSM 0.58% 92 $ 15.981K Jun 30, 2026
DFSV 0.55% 754,966 $ 151.378M Nov 12, 2026
MSSM 0.19% 8,247 $ 1.361M Aug 31, 2026
IALT 0.19% 77,971 $ 14.924M Nov 16, 2026
BDVL 0.18% 17,045 $ 3.262M Nov 16, 2026
DFAT 0.14% 223,278 $ 44.769M Nov 12, 2026
FTQI 0.12% 6,113 $ 1.17M Nov 16, 2026
DFAS 0.10% 164,948 $ 33.074M Nov 12, 2026
PINK 0.08% 1,431 $ 279.074K Nov 17, 2026
DFSU 0.05% 6,267 $ 1.257M Nov 12, 2026
DXUV 0.04% 13,297 $ 2.666M Nov 12, 2026
DFAC 0.03% 137,814 $ 27.633M Nov 12, 2026
JSTC 0.03% 515 $ 98.571K Nov 17, 2026
DFAU 0.03% 18,112 $ 3.632M Nov 12, 2026
DFUS 0.02% 24,885 $ 4.99M Nov 12, 2026
DFUV 0.02% 17,800 $ 3.569M Nov 12, 2026
DCOR 0.02% 35,643 $ 7.147M Nov 12, 2026
NTRL 0.00% 1,269 $ 0.00 Nov 16, 2026